Pharma BD Deal Intelligence
GSK and Alector entered a global development and commercialization collaboration (announced July 22, 2021; agreement effective August 17, 2021 after HSR clearance) for two progranulin-elevating monoclonal antibodies, latozinemab (AL001) and AL101/GSK4527226 (nivisnebart), targeting neurodegenerative diseases. Alector received $700M upfront ($500M in Q3 2021, $200M in Q1 2022) and was eligible for up to $1.5B in milestones, with 50/50 US profit share and ex-US tiered double-digit royalties. The collaboration thesis has since collapsed: latozinemab missed the clinical co-primary endpoint in the Phase 3 INFRONT-3 trial in FTD-GRN (topline October 21, 2025) and its development was discontinued, prompting Alector to cut ~49% of its workforce; nivisnebart was then discontinued in early Alzheimer's disease after the Phase 2 PROGRESS-AD trial was stopped for futility following an IDMC interim analysis (April 29, 2026). Both lead assets of the collaboration have now failed in the clinic.